These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 26189257)
21. CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish "MALOVA" Ovarian Cancer Study. Høgdall EV; Christensen L; Kjaer SK; Blaakaer J; Kjaerbye-Thygesen A; Gayther S; Jacobs IJ; Høgdall CK Gynecol Oncol; 2007 Mar; 104(3):508-15. PubMed ID: 17113137 [TBL] [Abstract][Full Text] [Related]
22. Expression of multiple human endogenous retrovirus surface envelope proteins in ovarian cancer. Wang-Johanning F; Liu J; Rycaj K; Huang M; Tsai K; Rosen DG; Chen DT; Lu DW; Barnhart KF; Johanning GL Int J Cancer; 2007 Jan; 120(1):81-90. PubMed ID: 17013901 [TBL] [Abstract][Full Text] [Related]
23. A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma. Sarivalasis A; Boudousquié C; Balint K; Stevenson BJ; Gannon PO; Iancu EM; Rossier L; Martin Lluesma S; Mathevet P; Sempoux C; Coukos G; Dafni U; Harari A; Bassani-Sternberg M; Kandalaft LE J Transl Med; 2019 Nov; 17(1):391. PubMed ID: 31771601 [TBL] [Abstract][Full Text] [Related]
24. The expression of six biomarkers in the four most common ovarian cancers: correlation with clinicopathological parameters. Lin CK; Chao TK; Yu CP; Yu MH; Jin JS APMIS; 2009 Mar; 117(3):162-75. PubMed ID: 19245589 [TBL] [Abstract][Full Text] [Related]
25. B7-H4 expression in ovarian serous carcinoma: a study of 306 cases. Liang L; Jiang Y; Chen JS; Niu N; Piao J; Ning J; Zu Y; Zhang J; Liu J Hum Pathol; 2016 Nov; 57():1-6. PubMed ID: 27349304 [TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. Nielsen JS; Jakobsen E; Hølund B; Bertelsen K; Jakobsen A Int J Gynecol Cancer; 2004; 14(6):1086-96. PubMed ID: 15571614 [TBL] [Abstract][Full Text] [Related]
27. [Expression of folate receptor alpha in ovarian epithelial tumors]. Shen DH; Xie JL; Zhang YL; Wang Y Zhonghua Bing Li Xue Za Zhi; 2010 Nov; 39(11):747-51. PubMed ID: 21215165 [TBL] [Abstract][Full Text] [Related]
28. HtrA1 expression and the prognosis of high-grade serous ovarian carcinoma: a cohort study using digital analysis. Gagné A; Têtu B; Orain M; Turcotte S; Plante M; Grégoire J; Renaud MC; Bairati I; Trudel D Diagn Pathol; 2018 Aug; 13(1):57. PubMed ID: 30131069 [TBL] [Abstract][Full Text] [Related]
29. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer. Skírnisdóttir I; Seidal T Int J Gynecol Cancer; 2011 Aug; 21(6):1024-31. PubMed ID: 21792012 [TBL] [Abstract][Full Text] [Related]
31. Differential expression of hypoxia-inducible protein 2 among different histological types of epithelial ovarian cancer and in clear cell adenocarcinomas. Nishimura S; Tsuda H; Ito K; Takano M; Terai Y; Jobo T; Kigawa J; Sugiyama T; Yaegashi N; Aoki D Int J Gynecol Cancer; 2010 Feb; 20(2):220-6. PubMed ID: 20134266 [TBL] [Abstract][Full Text] [Related]
32. Clinical significance of c-Met and phospho-c-Met (Tyr1234/1235) in ovarian cancer. Lim L; Wu CC; Hsu YT; Sun FJ; Chang CL Taiwan J Obstet Gynecol; 2019 Jan; 58(1):105-110. PubMed ID: 30638462 [TBL] [Abstract][Full Text] [Related]
34. [Expression and significance of PD-1 and PD-L1 in the specimens of epithelial ovarian cancer]. Ju C; Gao JC; Zhang PX; Zhang KN; Yang S; Kang TJ; Zhao HZ; Qi WJ; Zhang QP; Kong FD; Guan HW; Shi H Zhonghua Fu Chan Ke Za Zhi; 2020 Aug; 55(8):529-534. PubMed ID: 32854477 [No Abstract] [Full Text] [Related]
35. Aberrant expression of pim-3 promotes proliferation and migration of ovarian cancer cells. Zhuang H; Zhao MY; Hei KW; Yang BC; Sun L; Du X; Li YM Asian Pac J Cancer Prev; 2015; 16(8):3325-31. PubMed ID: 25921139 [TBL] [Abstract][Full Text] [Related]
36. HE4 tissue expression in borderline ovarian tumors: a pilot study by the tumorbank ovarian cancer network. Nassir M; Darb-Esfahani S; Richter R; Chekerov R; Hall C; Muallem MZ; Denkert C; Stamatian F; Fotopoulou C; Sehouli J; Braicu EI Anticancer Res; 2013 Apr; 33(4):1673-7. PubMed ID: 23564814 [TBL] [Abstract][Full Text] [Related]
37. Expression and correlation of Lewis y antigen and integrins α5 and β1 in ovarian serous and mucinous carcinoma. Li Q; Liu S; Lin B; Yan L; Wang Y; Wang C; Zhang S Int J Gynecol Cancer; 2010 Dec; 20(9):1482-9. PubMed ID: 21119363 [TBL] [Abstract][Full Text] [Related]
38. Taxol resistance among the different histological subtypes of ovarian cancer may be associated with the expression of class III beta-tubulin. Umezu T; Shibata K; Kajiyama H; Terauchi M; Ino K; Nawa A; Kikkawa F Int J Gynecol Pathol; 2008 Apr; 27(2):207-12. PubMed ID: 18317222 [TBL] [Abstract][Full Text] [Related]
39. [Ovarian cancer--modern approach to its origin and histogenesis]. Nowak-Markwitz E; Spaczyński M Ginekol Pol; 2012 Jun; 83(6):454-7. PubMed ID: 22880466 [TBL] [Abstract][Full Text] [Related]
40. Hepatocyte growth factor secreted by ovarian cancer cells stimulates peritoneal implantation via the mesothelial-mesenchymal transition of the peritoneum. Nakamura M; Ono YJ; Kanemura M; Tanaka T; Hayashi M; Terai Y; Ohmichi M Gynecol Oncol; 2015 Nov; 139(2):345-54. PubMed ID: 26335595 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]